公开(公告)号：US20110144056A1

公开(公告)日：2011-06-16

申请号：US12996435

申请日：2009-06-01

申请人： Linus S. Lin ,  Linda L. Chang ,  Harry Chobanian ,  Ravi P. Nargund

发明人： Linus S. Lin ,  Linda L. Chang ,  Harry Chobanian ,  Ravi P. Nargund

IPC分类号： A61K31/695 ,  C07D231/18 ,  A61K31/415 ,  C07D401/04 ,  C07D403/04 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/501 ,  C07F7/18 ,  C07D413/10 ,  A61K31/4245 ,  C07D401/14 ,  A61P19/02 ,  A61P3/10 ,  A61P21/00 ,  A61P29/00 ,  A61P25/06 ,  A61P25/28 ,  A61P25/16

CPC分类号： C07D471/04 ,  C07D231/18 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D413/10

摘要： The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease

摘要翻译： 本发明涉及可用作脂肪酸酰胺水解酶（FAAH）抑制剂的某些咪唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂，以及这些化合物及其制剂在治疗某些疾病，包括骨关节炎，类风湿性关节炎，糖尿病性神经病变，带状疱疹后神经痛，ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛，偏头痛，睡眠障碍，阿尔茨海默病和帕金森病

公开(公告)号：US08153626B2

公开(公告)日：2012-04-10

申请号：US12517836

申请日：2007-12-07

申请人： Robert K. Baker ,  Linda L. Chang ,  Marc Chioda ,  Harry R. Chobanian ,  Ying-Duo Gao ,  Yan Guo ,  Linus S. Lin ,  Ping Liu ,  Ravi P. Nargund ,  Kathleen M. Rupprecht ,  Shouwu Miao

发明人： Robert K. Baker ,  Linda L. Chang ,  Marc Chioda ,  Harry R. Chobanian ,  Ying-Duo Gao ,  Yan Guo ,  Linus S. Lin ,  Ping Liu ,  Ravi P. Nargund ,  Kathleen M. Rupprecht ,  Shouwu Miao

IPC分类号： A01N43/62 ,  A61K31/55 ,  C07D491/00 ,  C07D513/00 ,  C07D515/00 ,  C07D243/10 ,  C07D487/12

CPC分类号： C07D471/04 ,  C07D471/14

摘要： Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

摘要翻译： 某些新型取代的二氮杂类磺酰胺是人类bombesin受体的配体，特别是人类bombesin受体亚型-3（BRS-3）的选择性配体。 因此，它们可用于治疗，控制或预防对调节BRS-3的疾病和病症，例如肥胖症和糖尿病。

公开(公告)号：US20100317645A1

公开(公告)日：2010-12-16

申请号：US12517836

申请日：2007-12-07

申请人： Robert K. Baker ,  Linda L. Chang ,  Marc Chioda ,  Harry R. Chobanian ,  Ying-Duo Gao ,  Yan Guo ,  Linus S. Lin ,  Ping Liu ,  Ravi P. Nargund ,  Kathleen M. Rupprecht ,  Shouwu Miao

发明人： Robert K. Baker ,  Linda L. Chang ,  Marc Chioda ,  Harry R. Chobanian ,  Ying-Duo Gao ,  Yan Guo ,  Linus S. Lin ,  Ping Liu ,  Ravi P. Nargund ,  Kathleen M. Rupprecht ,  Shouwu Miao

IPC分类号： A61K31/551 ,  C07D487/04 ,  C07D498/14 ,  C07D487/14 ,  A61P3/10 ,  A61P3/04

CPC分类号： C07D471/04 ,  C07D471/14

摘要： Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

摘要翻译： 某些新型取代的二氮杂类磺酰胺是人类bombesin受体的配体，特别是人类bombesin受体亚型-3（BRS-3）的选择性配体。 因此，它们可用于治疗，控制或预防对调节BRS-3的疾病和病症，例如肥胖症和糖尿病。

公开(公告)号：US20090258884A1

公开(公告)日：2009-10-15

申请号：US12386336

申请日：2009-04-16

申请人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza, JR.

发明人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza, JR.

IPC分类号： A61K31/497 ,  C07D213/56 ,  A61K31/4412 ,  C07C235/00 ,  A61K31/165 ,  C07D401/12 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/506 ,  C07D249/04 ,  A61K31/4192 ,  C07D409/12 ,  A61K31/4436 ,  C07D413/12 ,  A61K31/4709 ,  A61P3/04

CPC分类号： C07D213/64 ,  C07C233/13 ,  C07C235/06 ,  C07C235/20 ,  C07C235/34 ,  C07C235/74 ,  C07C235/78 ,  C07C237/06 ,  C07C255/55 ,  C07C255/60 ,  C07C271/14 ,  C07C271/22 ,  C07C275/30 ,  C07C311/03 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D209/34 ,  C07D209/94 ,  C07D211/34 ,  C07D213/65 ,  C07D213/68 ,  C07D215/06 ,  C07D231/12 ,  C07D233/56 ,  C07D233/70 ,  C07D237/28 ,  C07D237/32 ,  C07D239/34 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D263/58 ,  C07D267/14 ,  C07D277/30 ,  C07D277/36 ,  C07D295/13 ,  C07D295/15 ,  C07D513/04

摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

公开(公告)号：US20080171692A1

公开(公告)日：2008-07-17

申请号：US12012463

申请日：2008-02-01

申请人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza

发明人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza

IPC分类号： A61K38/22 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/365 ,  A61P3/04 ,  A61K31/485 ,  A61K31/357 ,  A61K31/155

CPC分类号： C07D213/64 ,  C07C233/13 ,  C07C235/06 ,  C07C235/20 ,  C07C235/34 ,  C07C235/74 ,  C07C235/78 ,  C07C237/06 ,  C07C255/55 ,  C07C255/60 ,  C07C271/14 ,  C07C271/22 ,  C07C275/30 ,  C07C311/03 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D209/34 ,  C07D209/94 ,  C07D211/34 ,  C07D213/65 ,  C07D213/68 ,  C07D215/06 ,  C07D231/12 ,  C07D233/56 ,  C07D233/70 ,  C07D237/28 ,  C07D237/32 ,  C07D239/34 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D263/58 ,  C07D267/14 ,  C07D277/30 ,  C07D277/36 ,  C07D295/13 ,  C07D295/15 ,  C07D513/04

摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

公开(公告)号：US06855708B2

公开(公告)日：2005-02-15

申请号：US10096607

申请日：2002-03-13

申请人： Linus S. Lin ,  George Doherty ,  Shrenik K. Shah ,  Linda L. Chang ,  William K. Hagmann ,  Richard A. Mumford

发明人： Linus S. Lin ,  George Doherty ,  Shrenik K. Shah ,  Linda L. Chang ,  William K. Hagmann ,  Richard A. Mumford

IPC分类号： C07D401/12 ,  C07D487/04 ,  C07D498/04 ,  A61K31/55 ,  A61K31/47

CPC分类号： C07D401/12 ,  C07D487/04

摘要： Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

摘要翻译： 式I的化合物是VLA-4和/或α4/β7的拮抗剂，因此可用于抑制或预防细胞粘附和细胞粘附介导的病理学。 这些化合物可以配制成药物组合物，适用于治疗AIDS相关的痴呆，过敏性结膜炎，过敏性鼻炎，阿尔茨海默病，哮喘，动脉粥样硬化，自体骨髓移植，某些类型的毒性和免疫性肾炎， 接触皮肤过敏，包括溃疡性结肠炎和克罗恩病的炎性肠病，炎症性肺病，病毒感染的炎症后遗症，脑膜炎，多发性硬化，多发性骨髓瘤，心肌炎，器官移植，牛皮癣，肺纤维化，再狭窄，视网膜炎，类风湿性关节炎，败血症 关节炎，中风，肿瘤转移，葡萄膜炎和I型糖尿病。

公开(公告)号：US06559174B2

公开(公告)日：2003-05-06

申请号：US10097028

申请日：2002-03-13

申请人： Linus S. Lin ,  Shrenik K. Shah ,  Linda L. Chang ,  William K. Hagmann ,  Richard A. Mumford

发明人： Linus S. Lin ,  Shrenik K. Shah ,  Linda L. Chang ,  William K. Hagmann ,  Richard A. Mumford

IPC分类号： A61K3147

CPC分类号： C07D401/12 ,  A61K31/4709 ,  A61K31/4745 ,  C07D401/14 ,  C07D487/04

摘要： Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

公开(公告)号：US06972295B2

公开(公告)日：2005-12-06

申请号：US10387265

申请日：2003-03-12

申请人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza, Jr.

发明人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza, Jr.

IPC分类号： A61K31/165 ,  A61K31/27 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/403 ,  A61K31/405 ,  A61K31/415 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/423 ,  A61K31/426 ,  A61K31/428 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4436 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/505 ,  A61K31/5377 ,  A61K31/553 ,  A61P1/04 ,  A61P1/10 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/24 ,  A61P9/04 ,  A61P9/06 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P11/06 ,  A61P13/12 ,  A61P15/00 ,  A61P15/10 ,  A61P17/00 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P25/06 ,  A61P25/08 ,  A61P25/16 ,  A61P25/18 ,  C07C233/12 ,  C07C233/13 ,  C07C235/06 ,  C07C235/18 ,  C07C235/20 ,  C07C235/34 ,  C07C235/74 ,  C07C235/78 ,  C07C237/06 ,  C07C255/55 ,  C07C255/60 ,  C07C271/14 ,  C07C271/22 ,  C07C275/30 ,  C07C311/03 ,  C07C323/41 ,  C07D207/27 ,  C07D209/08 ,  C07D209/34 ,  C07D209/52 ,  C07D209/94 ,  C07D211/34 ,  C07D213/36 ,  C07D213/40 ,  C07D213/56 ,  C07D213/61 ,  C07D213/64 ,  C07D213/65 ,  C07D213/68 ,  C07D213/89 ,  C07D215/06 ,  C07D231/12 ,  C07D233/36 ,  C07D233/70 ,  C07D233/80 ,  C07D237/14 ,  C07D237/28 ,  C07D237/32 ,  C07D239/34 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D249/18 ,  C07D261/08 ,  C07D261/20 ,  C07D263/58 ,  C07D267/14 ,  C07D277/20 ,  C07D277/30 ,  C07D277/36 ,  C07D277/64 ,  C07D277/74 ,  C07D295/12 ,  C07D295/13 ,  C07D295/14 ,  C07D295/15 ,  C07D401/12 ,  C07D409/12 ,  C07D413/12 ,  C07D471/04 ,  C07D513/04 ,  C07D521/00 ,  A61K31/4412 ,  C07D213/70

CPC分类号： C07D213/64 ,  C07C233/13 ,  C07C235/06 ,  C07C235/20 ,  C07C235/34 ,  C07C235/74 ,  C07C235/78 ,  C07C237/06 ,  C07C255/55 ,  C07C255/60 ,  C07C271/14 ,  C07C271/22 ,  C07C275/30 ,  C07C311/03 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D209/34 ,  C07D209/94 ,  C07D211/34 ,  C07D213/65 ,  C07D213/68 ,  C07D215/06 ,  C07D231/12 ,  C07D233/56 ,  C07D233/70 ,  C07D237/28 ,  C07D237/32 ,  C07D239/34 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D263/58 ,  C07D267/14 ,  C07D277/30 ,  C07D277/36 ,  C07D295/13 ,  C07D295/15 ,  C07D513/04

摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗物质滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。

公开(公告)号：US07816534B2

公开(公告)日：2010-10-19

申请号：US12386336

申请日：2009-04-16

申请人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza, Jr.

发明人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza, Jr.

IPC分类号： A61K31/44 ,  C07D213/04 ,  C07D401/02 ,  C07D403/02 ,  C07D239/02

CPC分类号： C07D213/64 ,  C07C233/13 ,  C07C235/06 ,  C07C235/20 ,  C07C235/34 ,  C07C235/74 ,  C07C235/78 ,  C07C237/06 ,  C07C255/55 ,  C07C255/60 ,  C07C271/14 ,  C07C271/22 ,  C07C275/30 ,  C07C311/03 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D209/34 ,  C07D209/94 ,  C07D211/34 ,  C07D213/65 ,  C07D213/68 ,  C07D215/06 ,  C07D231/12 ,  C07D233/56 ,  C07D233/70 ,  C07D237/28 ,  C07D237/32 ,  C07D239/34 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D263/58 ,  C07D267/14 ,  C07D277/30 ,  C07D277/36 ,  C07D295/13 ,  C07D295/15 ,  C07D513/04

摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。

公开(公告)号：US07550489B2

公开(公告)日：2009-06-23

申请号：US12012463

申请日：2008-02-01

申请人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza, Jr.

发明人： William K. Hagmann ,  Linus S. Lin ,  Shrenik K. Shah ,  Ravindra N. Guthikonda ,  Hongbo Qi ,  Linda L. Chang ,  Ping Liu ,  Helen M. Armstrong ,  James P. Jewell ,  Thomas J. Lanza, Jr.

IPC分类号： A61K31/435

CPC分类号： C07D213/64 ,  C07C233/13 ,  C07C235/06 ,  C07C235/20 ,  C07C235/34 ,  C07C235/74 ,  C07C235/78 ,  C07C237/06 ,  C07C255/55 ,  C07C255/60 ,  C07C271/14 ,  C07C271/22 ,  C07C275/30 ,  C07C311/03 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07D209/34 ,  C07D209/94 ,  C07D211/34 ,  C07D213/65 ,  C07D213/68 ,  C07D215/06 ,  C07D231/12 ,  C07D233/56 ,  C07D233/70 ,  C07D237/28 ,  C07D237/32 ,  C07D239/34 ,  C07D249/04 ,  C07D249/08 ,  C07D249/12 ,  C07D263/58 ,  C07D267/14 ,  C07D277/30 ,  C07D277/36 ,  C07D295/13 ,  C07D295/15 ,  C07D513/04

摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.